COLA: Drug challenges and desensitization

Evaluation of drug allergy is difficult.  Clinical presentation is heterogeneous and can mimic many different pathophysiologic events.  Poor diagnostic techniques exist and patient history is often remote and poorly documented.

 

Session recorded on:   August 3, 2018

Speaker:  Rebecca Saff, MD

Price: $25 members,  $35 non-members

Viewers can earn credit by completing the posttest questions.
 

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

There is no commercial support for this activity.

Target Audience

Practicing allergists/immunologists

Fellows-in-Training

Learning Objectives

  • Discuss how to evaluate and manage patients with drug hypersensitivity reactions
  • Discuss diagnostic strategies of drug allergy (including skin testing, desensitization, drug challenge) and understand when each is appropriate
  • Review specific drug allergy scenarios for penicillin, NSAIDs, and chemotherapy
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner

Speaker, honorarium: Thermofisher, Boehringer Ingelheim

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner

Rebecca Saff, MD, Speaker

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/03/2018
Course expires: 
12/31/2019
Cost:
$35.00
Rating: 
0

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Accreditation Period

Course opens: 
08/03/2018
Course expires: 
12/31/2019

Price

Cost:
$35.00
Please login or create an account to take this course.